Cargando…

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection

The introduction of biologic drugs revolutionized the management of moderate-to-severe forms of psoriasis. However, safety concerns still remain, particularly on patient affected by opportunistic infections. In this scenario, the safety of biologic drugs in patient with HBV infection is debated. Glo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potestio, Luca, Piscitelli, Ilaria, Fabbrocini, Gabriella, Martora, Fabrizio, Ruggiero, Angelo, Megna, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911898/ https://www.ncbi.nlm.nih.gov/pubmed/36776245 http://dx.doi.org/10.2147/CCID.S403294

Ejemplares similares

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?
por: Martora, Fabrizio, et al.
Publicado: (2023)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

A case of linear psoriasis in a young patient with Down syndrome and review of the literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
por: Potestio, Luca, et al.
Publicado: (2023)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

Towards Personalized Medicine in Psoriasis: Current Progress
por: Camela, Elisa, et al.
Publicado: (2022)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

COVID‐19 vaccination and inflammatory skin diseases
por: Martora, Fabrizio, et al.
Publicado: (2022)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
por: Battista, Teresa, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Letter to the editor regarding article “Yalici‐Armagan B, Tabak GH, Dogan‐Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID‐19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5”
por: Potestio, Luca, et al.
Publicado: (2021)

Pemphigus vulgaris and COVID‐19 vaccination: Management and treatment
por: Martora, Fabrizio, et al.
Publicado: (2022)

A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus
por: Marasca, Claudio, et al.
Publicado: (2020)

Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
por: Megna, Matteo, et al.
Publicado: (2022)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511”
por: Potestio, Luca, et al.
Publicado: (2022)

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
por: Megna, Matteo, et al.
Publicado: (2021)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
por: Potestio, Luca, et al.
Publicado: (2023)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Letter to the editor regarding the article “Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610.”
por: Potestio, Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hk4as7cgdmtfa30ltgkpjb5plr